These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18097771)

  • 21. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
    J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study.
    Lindor NM; Johnson KJ; Harvey H; Shane Pankratz V; Domchek SM; Hunt K; Wilson M; Cathie Smith M; Couch F
    Fam Cancer; 2010 Dec; 9(4):495-502. PubMed ID: 20512419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 10-year performance of four models of breast cancer risk: a validation study.
    Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
    Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
    Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
    Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models.
    Lindor NM; Lindor RA; Apicella C; Dowty JG; Ashley A; Hunt K; Mincey BA; Wilson M; Smith MC; Hopper JL
    Fam Cancer; 2007; 6(4):473-82. PubMed ID: 17636425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
    Evans DG; Eccles DM; Rahman N; Young K; Bulman M; Amir E; Shenton A; Howell A; Lalloo F
    J Med Genet; 2004 Jun; 41(6):474-80. PubMed ID: 15173236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
    Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.
    de la Hoya M; Díez O; Pérez-Segura P; Godino J; Fernández JM; Sanz J; Alonso C; Baiget M; Díaz-Rubio E; Caldés T
    J Med Genet; 2003 Jul; 40(7):503-10. PubMed ID: 12843322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.
    Biswas S; Tankhiwale N; Blackford A; Barrera AM; Ready K; Lu K; Amos CI; Parmigiani G; Arun B
    Breast Cancer Res Treat; 2012 May; 133(1):347-55. PubMed ID: 22270937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
    Oliva L; Lozano R; Llácer C; Aragón I; Pajares BI; Sáez MI; Herrera-Imbroda B; Montesa A; Hernández D; Villatoro R; Otero A; Correa R; Grau G; Peinado P; Pacheco MI; García-Galisteo E; Rueda A; Machuca FJ; Alba E; Márquez-Aragonés A; Olmos D; Castro E
    Eur Urol Oncol; 2021 Apr; 4(2):315-318. PubMed ID: 31307957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.
    Bonaïti B; Alarcon F; Andrieu N; Bonadona V; Dondon MG; Pennec S; Stoppa-Lyonnet D; Bonaïti-Pellié C; Perdry H
    J Med Genet; 2014 Feb; 51(2):114-21. PubMed ID: 24343917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.
    Berrino J; Berrino F; Francisci S; Peissel B; Azzollini J; Pensotti V; Radice P; Pasanisi P; Manoukian S
    Fam Cancer; 2015 Mar; 14(1):117-28. PubMed ID: 25373702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.
    Evans DG; Woodward ER; Howell SJ; Verhoef S; Howell A; Lalloo F
    Fam Cancer; 2017 Apr; 16(2):173-179. PubMed ID: 27796713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.
    Kwong A; Wong CH; Suen DT; Co M; Kurian AW; West DW; Ford JM
    World J Surg; 2012 Apr; 36(4):702-13. PubMed ID: 22290208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
    MacInnis RJ; Bickerstaffe A; Apicella C; Dite GS; Dowty JG; Aujard K; Phillips KA; Weideman P; Lee A; Terry MB; Giles GG; Southey MC; Antoniou AC; Hopper JL
    Br J Cancer; 2013 Sep; 109(5):1296-301. PubMed ID: 23942072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.